Amylyx Pharmaceuticals, Inc.
AMLX
$14.44
-$0.44-2.96%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.34% | -100.08% | -100.32% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.34% | -100.08% | -100.32% |
| Cost of Revenue | -1.97% | -60.47% | -64.60% | -65.51% | -64.71% |
| Gross Profit | 3.23% | 36.04% | -45.80% | -471.35% | -182.01% |
| SG&A Expenses | -12.29% | -44.99% | -56.79% | -63.27% | -64.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.36% | -55.31% | -61.75% | -64.62% | -64.51% |
| Operating Income | 7.05% | 40.04% | 26.16% | -3.78% | -110.83% |
| Income Before Tax | 31.63% | 52.11% | 41.78% | -15.93% | -234.30% |
| Income Tax Expenses | 107.24% | 111.70% | -131.96% | -118.12% | -111.68% |
| Earnings from Continuing Operations | 31.41% | 52.03% | 42.47% | -13.10% | -207.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.41% | 52.03% | 42.47% | -13.10% | -207.84% |
| EBIT | 7.05% | 40.04% | 26.16% | -3.78% | -110.83% |
| EBITDA | 6.92% | 40.04% | 26.07% | -4.10% | -113.05% |
| EPS Basic | 51.43% | 64.99% | 52.85% | -2.45% | -197.69% |
| Normalized Basic EPS | 34.80% | 56.87% | 36.34% | 3.57% | -115.35% |
| EPS Diluted | 51.43% | 64.99% | 52.86% | -2.00% | -189.63% |
| Normalized Diluted EPS | 34.80% | 56.87% | 36.31% | 4.01% | -110.64% |
| Average Basic Shares Outstanding | 38.73% | 38.69% | 24.09% | 15.08% | 7.59% |
| Average Diluted Shares Outstanding | 38.73% | 38.69% | 23.28% | 13.35% | 4.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |